Trial design
TB
VIRUS, HEPATITIS C, TUBERCULOSIS
The study, which conducted in rural communities in Zhongmu County with an average TB incidence of 57 per 100,000 for three consecutive years (2015–2017), consisted of two phases: a community-level screening study based on chest digital radiography (DR) investigations (two-round screening survey, see Flowchart of the participant enrolment. ALT, alanine aminotransferase; AST, aspartate aminotransferase; DR, digital radiography; HCV, hepatitis C virus; QFT, QuantiFERON-TB Gold In-Tube; RCT, randomized controlled trial; TB, tuberculosis; ULN, upper limit of normal; WBC, white blood cell. Of the 44,500 recruited rural residents, 43,670 participants aged 18–75 years had complete results of chest radiography and questionnaire, 40,682 were excluded because of normal chest radiographic findings (This trial was registered at the Chinese Clinical Trial Registry (ChiCTR-1800018224). The protocol was approved by the ethics committees of the Institute of Pathogen Biology, Chinese Academy of Medical Sciences, Beijing, China (IPB-2018-03-12). Written informed consent was obtained from each study participant. Proswell Medical Company (Beijing, China) independently monitored the study during its implementation.